Maxim Group analyst Naz Rahman reiterated a Buy rating on Silexion Therapeutics yesterday and set a price target of $75.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Naz Rahman has given his Buy rating due to a combination of factors, primarily centered around the promising preclinical data for Silexion Therapeutics’ SIL-204. The therapy has shown significant tumor growth inhibition across various KRAS mutations, including pancreatic and colorectal cancer lines, with inhibition rates as high as 97%. This broad efficacy suggests SIL-204’s potential as a pan-KRAS treatment, which could expand its market opportunity significantly.
Furthermore, the recent warrant exercises have provided Silexion with additional capital, raising $1.8 million in gross proceeds, which strengthens their financial position. The upcoming Phase 2b/3 trials for SIL-204, along with planned regulatory meetings, indicate a clear path forward for the company’s development efforts. Overall, the combination of strong preclinical results, financial bolstering, and strategic planning supports the Buy rating for Silexion Therapeutics.
Rahman covers the Healthcare sector, focusing on stocks such as Kazia Therapeutics, Aytu BioScience, and Nuvectis Pharma. According to TipRanks, Rahman has an average return of -17.8% and a 29.08% success rate on recommended stocks.